Healthcare Finance News April 21, 2020
Susan Morse

Participation in the new COVID-19 clinical trials improvement activity carries a high weight from a scoring perspective.

Providers may now earn credit in the merit-based incentive payment system, or MIPS, by contributing to scientific research and evidence to fight the coronavirus.

The Centers for Medicare and Medicaid Services is encouraging clinicians to take MIPS credit for participation in clinical trials and reporting clinical information to the new COVID-19 Clinical Trials improvement activity.

MIPS is a performance-based track of the quality payment program that incentivizes quality and value.

CMS is encouraging clinicians such as physicians, physician assistants, nurse practitioners, and others, to contribute to research that will provide data to help drive improvement in patient care and develop innovative best practices...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: CMS, Govt Agencies, MACRA, Payment Models, Pharma, Provider, Value Based
Related Articles:
'Medicare Done Right,' explained: Ending MIPS and overhauling MACRA
CMS Suspends Eight MIPS Improvement Activities for 2025
CMS suspends 8 MIPS improvement activities
Study: Smaller Radiology Practices Struggle With MIPS Scoring
Optimizing MIPS Value Pathways (MVPs) for Oncology Practices in 2025

Share Article